Business
Zentalis Pharmaceuticals Announces Positive Initial Clinical Data on ZN-c3, its Wee1 Inhibitor, in Patients with Advanced Ovarian Cancer at AACR
ZN-c3 in combination with chemotherapy demonstrated strong anti-tumor activity in a heavily pretreated population, with an ORR of 30.2% across all evaluable
About this update from Zentalis Pharmaceuticals, Inc.
[{"type":"text","content":"ZN-c3 in combination with chemotherapy demonstrated strong anti-tumor activity in a heavily pretreated population, with an ORR of 30.2% across all evaluable chemotherapy cohorts ZN-c3 in combination with chemotherapy was well-tolerated, exhibiting a better hematologic and gastrointestinal tolerability profile within the Wee1 inhibitor class Mini symposium on the ZN-c3 uterine serous carcinoma (USC) expansion cohort to be presented on April 11, 2022 at 2:50 p.m. CT Updates on clinical and preclinical studies with ZN-c5 and ZN-d5 Company to host webcast event with key opinion leader, Kathleen Moore, MD, today, Friday, April 8 at 4:00 p.m. EDT NEW YORK and SAN DIEGO, April 08, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced initial efficacy and safety data from the ongoing Phase 1b trial of ZN-c3 in combination with chemotherapy in patients with platinum-resistant or -refractory ovarian cancer. Data were reviewed as a clinical poster during the American Association of Cancer Research (AACR) Annual Meeting, being held in New Orleans, Louisiana on April 8-13, 2022. “The initial combination clinical activity reported from our ongoing trial supports ZN-c3’s potential best-in-class efficacy and safety profile and for the first time, showcases its synergistic combinability with various chemotherapies,” commented Dr. Anthony Sun, Chairman and Chief Executive Officer of Zentalis. “Utilizing a continuous dosing regimen in patients with advanced disease, ZN-c3 demonstrated an Objective Response Rate of 30.2% across all cohorts – achieving up to 62.5% with one cohort – and a markedly better tolerability profile within the Wee1 inhibitor class. Based on these promising initial results, we believe the data support the development of a Phase 3 trial to further investigate this combination’s effect in ovarian cancer patients. We look forward to announcing our future development plans for this program before year-end and are motivated by the opportunity to potentially deliver an improved and best-in-class treatment option to patients.” Initial Efficacy and Safety Data The ongoing Phase 1b dose-escalation trial is evaluating the safety, tolerability...